Kala Bio Inc logo

Kala Bio Inc

1
NAS:KALA (USA)  
$ 7.84 +0.12 (+1.53%) 11:08 PM EST
At Loss
P/B:
1.91
Market Cap:
$ 21.11M
Enterprise V:
$ 1.16M
Volume:
9.71K
Avg Vol (2M):
23.55K
Also Trade In:
Volume:
9.71K
At Loss
Avg Vol (2M):
23.55K
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for Kala Bio Inc ( ) from 2017 to Mar 29 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Kala Bio stock (KALA) PE ratio as of Mar 29 2024 is 0. More Details

Kala Bio Inc (KALA) PE Ratio (TTM) Chart

To

Kala Bio Inc (KALA) PE Ratio (TTM) Historical Data

Total 1197
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
Kala Bio PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-03-29 At Loss 2024-01-25 At Loss
2024-03-28 At Loss 2024-01-24 At Loss
2024-03-27 At Loss 2024-01-23 At Loss
2024-03-26 At Loss 2024-01-22 At Loss
2024-03-25 At Loss 2024-01-19 At Loss
2024-03-22 At Loss 2024-01-18 At Loss
2024-03-21 At Loss 2024-01-17 At Loss
2024-03-20 At Loss 2024-01-16 At Loss
2024-03-19 At Loss 2024-01-12 At Loss
2024-03-18 At Loss 2024-01-11 At Loss
2024-03-15 At Loss 2024-01-10 At Loss
2024-03-14 At Loss 2024-01-09 At Loss
2024-03-13 At Loss 2024-01-08 At Loss
2024-03-12 At Loss 2024-01-05 At Loss
2024-03-11 At Loss 2024-01-04 At Loss
2024-03-08 At Loss 2024-01-03 At Loss
2024-03-07 At Loss 2024-01-02 At Loss
2024-03-06 At Loss 2023-12-29 At Loss
2024-03-05 At Loss 2023-12-28 At Loss
2024-03-04 At Loss 2023-12-27 At Loss
2024-03-01 At Loss 2023-12-26 At Loss
2024-02-29 At Loss 2023-12-22 At Loss
2024-02-28 At Loss 2023-12-21 At Loss
2024-02-27 At Loss 2023-12-20 At Loss
2024-02-26 At Loss 2023-12-19 At Loss
2024-02-23 At Loss 2023-12-18 At Loss
2024-02-22 At Loss 2023-12-15 At Loss
2024-02-21 At Loss 2023-12-14 At Loss
2024-02-20 At Loss 2023-12-13 At Loss
2024-02-16 At Loss 2023-12-12 At Loss
2024-02-15 At Loss 2023-12-11 At Loss
2024-02-14 At Loss 2023-12-08 At Loss
2024-02-13 At Loss 2023-12-07 At Loss
2024-02-12 At Loss 2023-12-06 At Loss
2024-02-09 At Loss 2023-12-05 At Loss
2024-02-08 At Loss 2023-12-04 At Loss
2024-02-07 At Loss 2023-12-01 At Loss
2024-02-06 At Loss 2023-11-30 At Loss
2024-02-05 At Loss 2023-11-29 At Loss
2024-02-02 At Loss 2023-11-28 At Loss
2024-02-01 At Loss 2023-11-27 At Loss
2024-01-31 At Loss 2023-11-24 At Loss
2024-01-30 At Loss 2023-11-22 At Loss
2024-01-29 At Loss 2023-11-21 At Loss
2024-01-26 At Loss 2023-11-20 At Loss

Kala Bio Inc (KALA) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Description
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing innovative therapies for rare and severe eye diseases. KALA's lead product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.